Case-Control Study of the Glycotest™ HCC Panel Vs AFP for the Detection of Early-stage Hepatocellular Carcinoma

Active, not recruitingOBSERVATIONAL
Enrollment

766

Participants

Timeline

Start Date

May 22, 2019

Primary Completion Date

August 25, 2023

Study Completion Date

December 31, 2025

Conditions
Carcinoma, HepatocellularCirrhosis, Liver
Trial Locations (20)

10016

NYU Langone Health, New York

10029

Icahn School of Medicine at Mount Sinai, New York

10467

Montefiore Medical Center, The Bronx

19104

Hospital of the University of Pennsylvania (HUP), Philadelphia

21201

University of Maryland, Baltimore, Baltimore

32608

University of Florida, Gainesville

33125

Miami VA Healthcare System, Miami

48109

University of Michigan, Ann Arbor

48202

Henry Ford Health System, Detroit

55905

Mayo Clinic, Rochester

60611

Northwestern University, Chicago

75201

Baylor Scott & White Research Institute, Dallas

75390

The University of Texas Southwestern Medical Center, Dallas

77030

Baylor College of Medicine, Houston

90048

Cedars- Sinai Medical Center, Los Angeles

90095

University of California Los Angeles, Los Angeles

91120

Hebrew University- Hadassah Medical Center, Jerusalem

94115

Kaiser Permanente Northern California, San Francisco

University of California- San Francisco, San Francisco

94304

Stanford University School of Medicine, Stanford

All Listed Sponsors
lead

Glycotest, Inc.

INDUSTRY